Sign in

    Adam Lowensteiner

    Research Analyst at Lytham Partners

    Adam Lowensteiner is Vice President at Lytham Partners, specializing in investor relations for micro and small-cap companies across sectors such as healthcare, technology, cannabis, and industrials. He has worked directly with firms including Aurora Spine Corporation and has a longstanding reputation for expanding the investor audience and facilitating corporate access through high-profile conferences. With a career spanning over two decades, Adam began as a Senior Research Analyst at Individual Investor Group, held sell-side analyst roles at CJS Securities, and led client engagement at Wolfe Axelrod Weinberger Associates before joining Lytham Partners. He holds a Bachelor of Science in Finance from the Sy Syms School of Business at Yeshiva University, though no specific FINRA registrations or ranking metrics are publicly reported.

    Adam Lowensteiner's questions to CHARLES & COLVARD (CTHR) leadership

    Adam Lowensteiner's questions to CHARLES & COLVARD (CTHR) leadership • Q1 2024

    Question

    The analyst inquired about the future of moissanite given the rise of lab-grown diamonds, what the company is seeing with repeat customers, and the company's NASDAQ compliance status given the stock price is below $1.

    Answer

    The executive explained that they will continue to grow lab-grown diamonds but are also working on a new value proposition for moissanite to differentiate it, which will be announced soon. Repeat customer rates have increased from a 17-19% range to 23% due to retargeting and new fashion items. Regarding NASDAQ compliance, the deadline is December 11, after which they can file for a 6-month extension, but the primary plan is to drive business results to increase the stock price organically.

    Ask Fintool Equity Research AI